PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1128746
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1128746
Global underactive bladder market is projected to register a CAGR of 5.1% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029.
Global Underactive Bladder Market, By Treatment (Pharmacotherapy, Surgical Methods, Urethral Assist Device, and Stem Cell and Gene Therapies), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Clinics, Academic and Research Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others), Country (U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, and Rest of Middle East and Africa) Industry Trends and Forecast to 2029.
Rising prevalence of bladder disorders
Increasing research and development to develop innovative treatments
Rising product launches
Market Players
Astellas Pharma Inc.
Aurobindo Pharma.
Boehringer Ingelheim International GmbH
Macleods Pharmaceuticals Ltd.
Orion Corporation
ONO PHARMACEUTICAL CO., LTD.
Novartis AG
Pfizer Inc.
Cipla Inc.
Dr. Reddy's Laboratories Ltd.
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
Almirall, S.A
Glenwood
Vesiflo, Inc.
Alkem Labs.